The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - ARIAD
Stock and Other Ownership Interests - ARIAD
 
Honoraria - ARIAD; AstraZeneca; Novartis; Pfizer; Roche
Consulting or Advisory Role - ARIAD; AstraZeneca; Novartis; Pfizer; Roche
Speakers' Bureau - AstraZeneca; Roche
Research Funding - ARIAD; AstraZeneca; Clovis Oncology; Daiichi Sankyo; Ignyta; Novartis; Pfizer; Roche
Activity of brigatinib (BRG) in crizotinib (CRZ)-resistant ALK+ NSCLC patients (pts) according to ALK plasma mutation status.
 
Lyudmila Bazhenova
Stock and Other Ownership Interests - Epic Sciences
Consulting or Advisory Role - Abbvie; ARIAD; AstraZeneca; Bristol-Myers Squibb; Genentech/Roche; Genoptix; Heat Biologics; Novartis; Pfizer; Trovagene
Speakers' Bureau - AstraZeneca; Genentech; Novartis; Pfizer
Research Funding - BeyondSpring Pharmaceuticals
 
J. Graeme Hodgson
Employment - ARIAD
Stock and Other Ownership Interests - ARIAD
 
Corey J. Langer
Honoraria - Bristol-Myers Squibb; Genentech/Roche; Lilly/ImClone
Consulting or Advisory Role - Abbott Biotherapeutics; ARIAD; Bayer/Onyx; Bristol-Myers Squibb; Cancer Support Community; Celgene; Clarient; Clovis Oncology; Genentech/Roche; Lilly/ImClone; Merck
Research Funding - Advantagene (Inst); Ariad (Inst); Celgene (Inst); Clovis Oncology (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Inovio Pharmaceuticals (Inst); Merck (Inst); Stem CentRx (Inst)
 
George R. Simon
Consulting or Advisory Role - ARIAD; Boehringer Ingelheim; Celgene; Merck; Roche/Genentech
Speakers' Bureau - Celgene; Roche/Genentech
 
Scott N. Gettinger
Consulting or Advisory Role - ARIAD; Bristol-Myers Squibb; Janssen
Research Funding - ARIAD; AstraZeneca/MedImmune; Boehringer Ingelheim; Bristol-Myers Squibb; Incyte; Pfizer; Roche/Genentech
 
Sai-Hong Ignatius Ou
No Relationships to Disclose
 
Karen L. Reckamp
Consulting or Advisory Role - Amgen; ARIAD; Astellas Pharma; Boehringer Ingelheim; Euclises; Nektar
Research Funding - Adaptimmune (Inst); ARIAD (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Eisai (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Pfizer (Inst); Pfizer (Inst); Xcovery (Inst)
 
Howard Jack West
Consulting or Advisory Role - ARIAD; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Genentech/Roche; Guardant Health; Merck; Novartis
Speakers' Bureau - ARIAD; Genentech/Roche
 
Alberto Chiappori
Honoraria - Boehringer Ingelheim; Celgene; Merck; Novartis; Pfizer; Roche/Genentech
Consulting or Advisory Role - ARIAD; Lilly; Roche/Genentech
 
Han A. Koh
No Relationships to Disclose
 
Julian R. Molina
No Relationships to Disclose
 
Alice Tsang Shaw
Honoraria - Foundation medicine; Novartis; Pfizer; Roche/Genentech
Consulting or Advisory Role - ARIAD; Blueprint Medicines; Daiichi Sankyo; EMD Serono; Genentech; Ignyta; KSQ Therapeutics; Novartis; Pfizer; Roche; Taiho Pharmaceutical
Research Funding - Novartis; Pfizer; Roche/Genentech
 
Jyoti D. Patel
Consulting or Advisory Role - Abbvie; ARIAD
 
Justin Peter Favaro
No Relationships to Disclose
 
Jeff Haney
Employment - ARIAD
Stock and Other Ownership Interests - ARIAD
 
William Reichmann
No Relationships to Disclose
 
David Kerstein
Employment - ARIAD
Stock and Other Ownership Interests - ARIAD
 
Victor M. Rivera
Employment - ARIAD
Stock and Other Ownership Interests - ARIAD
 
D. Ross Camidge
Honoraria - ARIAD
Research Funding - ARIAD